Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder

被引:21
作者
Belgaied, Wael [1 ]
Sarnp, Jennifer [2 ]
Vimont, Alexandre [1 ]
Remuzat, Cecile [1 ]
Aballea, Samuel [1 ]
El Hammi, Emna [1 ]
Kooli, Amna [1 ]
Toumi, Mondher [1 ,3 ]
Akhras, Kasem [2 ]
机构
[1] Creativ Ceutical, Deerfield, IL USA
[2] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[3] Univ Lyon 1, UFR Odontol, F-69372 Lyon, France
关键词
Cognitive dysfunction; Schizophrenia; Major depressive disorder; Bipolar disorder; Cognitive instruments; Survey; NEUROCOGNITIVE IMPAIRMENT; BATTERY;
D O I
10.1016/j.euroneuro.2013.11.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As more evidence points to the association of cognitive dysfunction with mental health disorders, the assessment of cognitive function in routine clinical care of these disorders is increasingly important. Despite this, it remains unknown how cognitive function is measured in routine clinical practice. The objective of this study was to assess psychiatrists awareness of cognitive dysfunction in mental health disorders and their methods of cognitive assessment. An online survey was disseminated to psychiatrists in Europe, Asia, Australia and the United States. The survey asked about their perceptions of cognitive dysfunction in several mental health disorders, knowledge of cognitive assessment, method of cognitive assessment, and instruments used to measure cognitive function. Among the 61 respondents, most perceived that schizophrenia was associated with the greatest cognitive dysfunction. Many were unaware whether guidelines were available on cognitive assessment. In schizophrenia, 59% of psychiatrists reportedly used cognitive instruments, while the remainder relied solely on patient history interviews. The use of instruments to assess cognition in major depressive disorder (MDD) and bipolar disorder (BPD) was lower, 38% and 37% respectively. Of the reported instruments used, only a few were actually appropriate for use in the diseases of interest (12% in schizophrenia, 3% in MDD and 0% in BPD). Other instruments reported were clinical measures that did not assess cognition. These findings reveal some inconsistencies in psychiatrists' routine clinical evaluation of cognitive function. There appeared to be low use of true cognitive assessment instruments in clinical practice and confusion regarding what constituted a cognitive assessment instrument. (C) 2013 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 28 条
  • [1] [Anonymous], DEPRESS RES TREAT
  • [2] Cognitive Impairment in Schizophrenia and Affective Psychoses: Implications for DSM-V Criteria and Beyond
    Bora, Emre
    Yucel, Murat
    Pantelis, Christos
    [J]. SCHIZOPHRENIA BULLETIN, 2010, 36 (01) : 36 - 42
  • [3] Screening for dementia in primary care: A summary of the evidence for the US Preventive Services Task Force
    Boustani, M
    Peterson, B
    Hanson, L
    Harris, R
    Lohr, KN
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (11) : 927 - 937
  • [4] Screening for cognitive impairment in general practice: Toward a consensus
    Brodaty, H
    Clarke, J
    Ganguli, M
    Grek, A
    Jorm, AF
    Khachaturian, Z
    Scherr, P
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (01) : 1 - 13
  • [5] The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?
    Buchanan, Robert W.
    Keefe, Richard S. E.
    Umbricht, Daniel
    Green, Michael F.
    Laughren, Thomas
    Marder, Stephen R.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 (06) : 1209 - 1217
  • [6] A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia.
    Buchanan, RW
    Davis, M
    Goff, D
    Green, MF
    Keefe, RSE
    Leon, AC
    Nuechterlein, KH
    Laughren, T
    Levin, R
    Stover, E
    Fenton, W
    Marder, SR
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (01) : 5 - 19
  • [7] Can doctors predict patients' abbreviated mental test scores
    Burleigh, E
    Reeves, I
    McAlpine, C
    Davie, J
    [J]. AGE AND AGEING, 2002, 31 (04) : 303 - 306
  • [8] A review of screening tests for cognitive impairment
    Cullen, Breda
    O'Neill, Brian
    Evans, Jonathan J.
    Coen, Robert F.
    Lawlor, Brian A.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (08) : 790 - 799
  • [9] Psychosocial and neurocognitive profiles in depressed patients with major depressive disorder and bipolar disorder
    Godard, Julie
    Grondin, Simon
    Baruch, Philippe
    Lafleur, Martin F.
    [J]. PSYCHIATRY RESEARCH, 2011, 190 (2-3) : 244 - 252
  • [10] Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
    Green, MF
    Nuechterlein, KH
    Gold, JM
    Barch, DM
    Cohen, J
    Essock, S
    Fenton, WS
    Frese, F
    Goldberg, TE
    Heaton, RK
    Keefe, RSE
    Kern, RS
    Kraemer, H
    Stover, E
    Weinberger, DR
    Zalcman, S
    Marder, SR
    [J]. BIOLOGICAL PSYCHIATRY, 2004, 56 (05) : 301 - 307